Why the study?
To evaluate the safety and efficacy of apixaban for treating nonvalvular atrial fibrillation or venous thromboembolism in patients receiving peritoneal dialysis.
Does apixaban improve safety and efficacy compared to standard therapy in patients receiving peritoneal dialysis for nonvalvular atrial fibrillation or venous thromboembolism?
Does apixaban improve safety and efficacy compared to standard therapy in patients receiving peritoneal dialysis for nonvalvular atrial fibrillation or venous thromboembolism?
Apixaban may be a safe and effective alternative to warfarin in patients on peritoneal dialysis, though data specific to this population remains extremely limited.
Answers are grounded in this paper and cite their sources.
Apixaban use in peritoneal dialysis lacks robust data; leaves open optimal dosing and safety for AF or VTE.
Objective: To review the safety and efficacy of apixaban for the treatment of nonvalvular atrial fibrillation or venous thromboembolism in patients receiving peritoneal dialysis (PD). Data Sources: A PubMed and MEDLINE search was conducted through December 2020 using the following keywords and Medical Subject Headings (MeSH) terms alone or in various combinations: apixaban, peritoneal dialysis, continuous ambulatory peritoneal dialysis, end-stage renal disease, and hemodialysis. Study Selection and Data Extraction: English-language studies evaluating clinical outcomes pertaining to the use of apixaban in end stage renal disease (ESRD), which included patients receiving peritoneal dialysis were eligible for inclusion. Data Synthesis: Four studies were identified that met inclusion for this review, all retrospective in nature. These studies compared the safety and efficacy of apixaban with standard therapy in ESRD included patients on dialysis, with a very limited number of subjects receiving PD. In these studies, apixaban was shown to be potentially safer and more effective than warfarin. Outcomes did not differentiate between patients receiving PD or not. Conclusions: Use of apixaban in patients receiving PD may be safe and effective based on data from limited patients. Pharmacokinetics and pharmacodynamics of apixaban in the PD setting is an important question that clinicians should consider with use of this medication in the ESRD population. More studies focusing on the PD population are needed to better assess the use of apixaban in this understudied population.
No takes yet. Share an insight, caveat, or question.
Amani et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: